trending Market Intelligence /marketintelligence/en/news-insights/trending/d9feksyctz7pjhtxclgzla2 content esgSubNav
In This List

Seres Therapeutics adds former Novartis executive to board

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints

Blog

Shore Capital is Now Available in S&P Global’s Aftermarket Research Collection


Seres Therapeutics adds former Novartis executive to board

Cambridge, Mass.-based biotechnology company Seres Therapeutics Inc. appointed Meryl Zausner as a board member.

Zausner previously served as chief financial and administrative officer of Novartis AG unit Novartis Pharmaceuticals Corp. and a member of the U.S. pharmaceutical executive committee and global finance leadership team.

Seres Therapeutics develops medicines using live bacteria to treat diseases resulting from functional deficiencies of microorganisms within the body.